Sandoz Group AG (LTS:0SAN) Loans Receivable: CHF0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0SAN Sandoz Group AG LTS:0SAN
38 GF Score
Price CHF72.76
GF Value CHF48.34
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sandoz Group AG Loans Receivable?

Sandoz Group AG LTS:0SAN -0.01% 38 Loans Receivable is CHF0 Mil as of Jun. 2026. GuruFocus rates LTS:0SAN with a GF Score™ of 38/100 and a GF Value™ of CHF48.34 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Sandoz Group AG's Loans Receivable for the quarter that ended in Jun. 2026 was CHF0 Mil.

Sandoz Group AG Loans Receivable Related Terms

Sandoz Group AG Loans Receivable Historical Data

* Premium members only.

The historical data trend for Sandoz Group AG's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sandoz Group AG Loans Receivable Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Loans Receivable
0.00 0.00 0.00 0.00

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Loans Receivable Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
LTS:0SAN
38GF Score
Sandoz Group AG LTS:0SAN
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sandoz Group AG Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of CHF0 Mil mean?
Sandoz Group AG (LTS:0SAN) has a Loans Receivable of CHF0 Mil as of Jun. 2026. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Sandoz Group AG and its competitors.
Is Sandoz Group AG's Loans Receivable too high?
Sandoz Group AG's current Loans Receivable is CHF0 Mil. Overall, Sandoz Group AG has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sandoz Group AG's Loans Receivable compare to ZTS and UTHR?
Sandoz Group AG's Loans Receivable of CHF0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Drug Manufacturers company?
A good Loans Receivable depends on the Drug Manufacturers industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Sandoz Group AG and its competitors. Sandoz Group AG's current Loans Receivable is CHF0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sandoz Group AG stock overvalued right now?
Based on GuruFocus' analysis, Sandoz Group AG (LTS:0SAN) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF48.34, compared to a current price of CHF72.76 — trading 50.5% above its estimated fair value. The current Loans Receivable is CHF0 Mil. Sandoz Group AG's overall GF Score™ is 38/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Sandoz Group AG (LTS:0SAN), the current Loans Receivable is CHF0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sandoz Group AG (LTS:0SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sandoz Group AG stock appears to be overvalued. The current stock price of CHF72.76 is trading 50.5% above its estimated GF Value™ of CHF48.34. GuruFocus considers Sandoz Group AG to be Significantly Overvalued.

Key valuation signals for LTS:0SAN:

  • Loans Receivable: CHF0 Mil
  • GF Value™: CHF48.34 vs. price of CHF72.76 (50.5% above fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the LTS:0SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sandoz Group AG Business Description

Address Centralbahnstrasse 4, Basel, CHE, 4051
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $11 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among the leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006, as well as the first US biosimilar, Zarxio, in 2015. It has over 10 launched biosimilars in a number of markets and over 20 assets in its pipeline.
38GF Score

Get the complete analysis for LTS:0SAN

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF72.76
Price
CHF48.34
GF Value